Brigitte Dréno

Beyond beauty: Neurocosmetics, the skin-brain axis, and the future of emotionally intelligent skincare

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024

Development of the acne-specific quality of life questionnaire Quality of Life Relevance-Acne

54772 Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - Update 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

The Role and Benefits of Dermocosmetics in Acne Management in Japan

The Personalized Acne Treatment Tool — Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of Experts

Isotretinoin‐associated acne fulminans: A multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee

A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients

Isotretinoin Laboratory Monitoring in Acne Treatment

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks

Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents

5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

The Personalised Acne Care Pathway—Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts

Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panel

Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention